194032-34-3Relevant academic research and scientific papers
ROCK KINASE INHIBITORS
-
, (2020/05/29)
The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR
-
, (2017/06/12)
The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.
Isoquinoline derivatives and drugs
-
, (2008/06/13)
PCT No. PCT/JP97/00240 Sec. 371 Date Jul. 29, 1998 Sec. 102(e) Date Jul. 29, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/28130 PCT Pub. Date Aug. 7, 1997The invention relates to a compound of the following general formula [I] or a medicinally acceptable salt thereof, or a solvate thereof, wherein R1 represents alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano, or halogen; R2 represents hydrogen, hydroxy, or halogen; R3 represents hydrogen, alkyl, or amidino; Ring A represents a 5 to 11-membered cyclic amino group which may be substituted, which cyclic amino group may be bridged between two carbon atoms in optional positions. The compound of this invention is useful for the prevention or treatment of cerebral tissue impairment due to the vasospasm following cerebral hemorrhage.
